More recently, a monoclonal antibody (RG7155) directed against human diffuse-type giant cell tumors CSF-1R has been described which improves the objective clinical responses and increases the CD8+/CD4+ T cell ratio through potently and selectively inhibiting CSF-1R signaling by blocking receptor dimerization induced by CSF-1 [151]. The gene discussed is CSF1R; the disease is tenosynovial giant cell tumor, diffuse type.